人类对基因减毒疟原虫的相关体液免疫和细胞免疫。
Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans.
作者信息
Colstrup Emil, Nakajima Rie, Krol Jelte M M, Lamers Olivia A C, de Assis Rafael R, Jain Aarti, Jasinskas Algis, Iliopoulou Eva, de Bes-Roeleveld Helena M, Franke-Fayard Blandine M D, Roestenberg Meta, Felgner Philip L, Murugan Rajagopal
机构信息
Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, Irvine, CA, USA.
出版信息
iScience. 2025 May 5;28(6):112589. doi: 10.1016/j.isci.2025.112589. eCollection 2025 Jun 20.
Malaria caused by remains one of the major infectious diseases with a high burden in Sub-Saharan Africa. In spite of the advancements made in vaccine development and implementation in endemic countries, sterile and durable protection has not been achieved. Recently, we have shown the superior protective capacity of whole sporozoites attenuated to arrest late (GA2) but not early (GA1) during the liver stage development in a controlled human malaria infection study. Here we report the breadth of antigens targeted by hitherto understudied parasite liver stage immunity and convey the coherence between humoral and cellular immunity observed in our clinical study. Our findings uncover the underlying immunogenic differences between early- and late-liver stage arresting parasites and identify key liver stage antigens for future vaccine development focused on inducing sterile immunity to malaria.
由……引起的疟疾仍然是撒哈拉以南非洲地区负担沉重的主要传染病之一。尽管在疟疾流行国家的疫苗研发和实施方面取得了进展，但尚未实现无菌和持久的保护。最近，在一项受控人类疟疾感染研究中，我们已经表明，在肝脏阶段发育过程中减毒以阻止晚期（GA2）而非早期（GA1）的全子孢子具有卓越的保护能力。在此，我们报告了迄今研究不足的寄生虫肝脏阶段免疫所靶向的抗原广度，并阐述了我们临床研究中观察到的体液免疫和细胞免疫之间的一致性。我们的研究结果揭示了早期和晚期肝脏阶段停滞寄生虫之间潜在的免疫原性差异，并确定了未来疫苗研发的关键肝脏阶段抗原，重点是诱导对疟疾的无菌免疫。
Zotero 插件